Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
BM BMRN BIOMARIN PHARMACEUTICAL INC FY ended Feb 19, 2026 | $64.67 | $12.52B | $10.76B | $3.22B | $567.70M | $348.90M | 35.93x | 3.89x | 18.47x |
RE REPL Replimune Group, Inc. FY ended Jun 25, 2026 | $15.50 | $1.46B | $1.35B | — | -$309.80M | -$313.94M | -4.59x | — | — |
PT PTCT PTC THERAPEUTICS, INC. FY ended Feb 18, 2026 | $70.09 | $5.85B | $6.35B | $1.73B | $741.26M | $682.64M | 9.01x | 3.38x | 8.46x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 15.32x | 3/4 | -$11.09B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 4.54x | 3/4 | $9.99B | $94.53 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 17.68x | 4/4 | -$12.62B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
BM BMRN BIOMARIN PHARMACEUTICAL INC FY ended Feb 19, 2026 | $64.67 | $12.52B | $10.76B | $3.22B | $567.70M | $348.90M | 35.93x | 3.89x | 18.47x |
RE REPL Replimune Group, Inc. FY ended Jun 25, 2026 | $15.50 | $1.46B | $1.35B | — | -$309.80M | -$313.94M | -4.59x | — | — |
PT PTCT PTC THERAPEUTICS, INC. FY ended Feb 18, 2026 | $70.09 | $5.85B | $6.35B | $1.73B | $741.26M | $682.64M | 9.01x | 3.38x | 8.46x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 15.32x | 3/4 | -$11.09B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 4.54x | 3/4 | $9.99B | $94.53 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 17.68x | 4/4 | -$12.62B | — | Target fundamentals do not produce a usable positive equity value. |
